Medivation Appoints Patrick Machado to Board of Directors
SAN FRANCISCO, CA -- (Marketwired) -- 04/17/14 -- Medivation, Inc.
(NASDAQ: MDVN) today announced that Patrick Machado has been
appointed to the Company's board of directors. Mr. Machado recently
retired from his role as chief financial and business officer, and
will formally retire from Medivation on April 18, 2014.
"For the past nine years of having the honor of serving on the board
of directors of Medivation, including seven as chairman, I've had the
opportunity to observe the keen insight and vision that Pat Machado
has brought to Medivation," said Kim D. Blickenstaff, chairman of
Medivation, Inc. "I look forward to working with Pat in his new role,
as he continues to help guide Medivation's efforts to develop novel
therapies for serious diseases."
Mr. Machado previously served as Medivation's chief business officer
since December 2009 and its chief financial officer since December
2004. From 1998 until 2001, Mr. Machado was employed by ProDuct
Health, Inc., a privately held medical device company, as vice
president, chief financial officer and general counsel (1998-2000)
and as senior vice president and chief financial officer (2000-2001).
From 2001 until 2002, Mr. Machado served as a consultant to Cytyc
Corporation to assist with transitional matters related to Cytyc
Corporation's acquisition of ProDuct Health, Inc. Mr. Machado
received a J.D. from Harvard Law School and a B.A. and B.S. in German
and Economics, respectively, from Santa Clara University.
Medivation, Inc. is a biopharmaceutical company focused on the rapid
development of novel therapies to treat serious diseases for which
there are limited treatment options. Medivation aims to transform the
treatment of these diseases and offer hope to critically ill patients
and their families. For more information, please visit us at
Sr. Director, Investor Relations
Press spacebar to pause and continue. Press esc to stop.